NCT05768425View on ClinicalTrials.gov

DIagnostic Biomarkers and Symptoms in Patients With Alzheimer's Disease and Lewy bodY Dementia

Active, not recruitingOBSERVATIONAL
Enrollment

55

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

December 31, 2032

Study Completion Date

December 31, 2032

Conditions
Dementia With Lewy BodiesAlzheimer DiseaseMild Cognitive Impairment
Interventions
DIAGNOSTIC_TEST

Real-time quaking-induced conversion (RT-QuIC)

RT-QuIC measures the ability of alpha-synuclein (aSyn) to misfold other aSyn proteins and is an amplification technique.

DIAGNOSTIC_TEST

Cognitive test

Minimal Mental State examination (MMSE), Montreal Cognitive Assessment (MoCA)

DIAGNOSTIC_TEST

Motor examination

Unified Parkinsons Rating Scale (UPDRS)

Trial Locations (1)

2100

Danish Dementia Research Centre, Copenhagen

All Listed Sponsors
collaborator

Danish Reference Center for Prion Diseases, Rigshospitalet

UNKNOWN

collaborator

Department of Otorhinolaryngology, Head and Neck Surgery & Audiology, Rigshospitalet

UNKNOWN

lead

Danish Dementia Research Centre

NETWORK

NCT05768425 - DIagnostic Biomarkers and Symptoms in Patients With Alzheimer's Disease and Lewy bodY Dementia | Biotech Hunter | Biotech Hunter